A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America.

Details

Language :

English

ISSN :

00916749

Volume :

139

Database :

Supplemental Index

Journal :

Journal of Allergy & Clinical Immunology

Publication Type :

Academic Journal

Accession number :

121130833

Full Text :

https://doi.org/10.1016/j.jaci.2016.12.700